Crinetics Pharmaceuticals, Inc. cash flow to debt ratio of -778.56% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Crinetics Pharmaceuticals, Inc.'s free cash flow has decreased 66.95% from $-229.81M last year to $-383.68M, signaling decreasing performance

Crinetics Pharmaceuticals, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Crinetics Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 0.04 last year to 0.00 today, signaling strengthened financials

Crinetics Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

Crinetics Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Crinetics Pharmaceuticals, Inc.'s profit margin has increased (-95.86%) in the last year from -28.72K% to -1.19K%, signaling increasing performance

Crinetics Pharmaceuticals, Inc.'s short-term assets of $1.05B exceed its short-term liabilities of $85.07M

Crinetics Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Crinetics Pharmaceuticals, Inc.'s return on equity of -44.22%, is lower than 15.00%, indicating bad performance

Crinetics Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Crinetics Pharmaceuticals, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Crinetics Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Crinetics Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

Crinetics Pharmaceuticals, Inc.'s yearly earnings has decreased 55.93% since last year from $-298.41M to $-465.32M, signaling decreasing performance

Crinetics Pharmaceuticals, Inc.'s yearly revenue has increased 640.71% since last year from $1.04M to $7.70M, signaling increasing performance

ROIC -44.21% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Crinetics Pharmaceuticals, Inc.'s 3-year revenue CAGR of 17.56% is positive, indicating growing revenue over the past 3 years

Crinetics Pharmaceuticals, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Crinetics Pharmaceuticals, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Crinetics Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Crinetics Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Crinetics Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Crinetics Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Crinetics Pharmaceuticals, Inc. is overvalued relative to its fair value price of -106.34 based on Earnings Fair Value model

Crinetics Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Crinetics Pharmaceuticals, Inc. has a price-to-book ratio of 7.45x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Crinetics Pharmaceuticals, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue